New York State Teachers Retirement System Has $2.95 Million Stake in Inari Medical, Inc. (NASDAQ:NARI)

New York State Teachers Retirement System trimmed its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,701 shares of the company’s stock after selling 200 shares during the period. New York State Teachers Retirement System owned approximately 0.10% of Inari Medical worth $2,946,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of Inari Medical during the fourth quarter worth approximately $45,000. KBC Group NV lifted its position in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after purchasing an additional 498 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Inari Medical by 66.8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after buying an additional 786 shares during the last quarter. Covestor Ltd raised its stake in shares of Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Inari Medical by 44.2% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock worth $128,000 after buying an additional 954 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on NARI. Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Piper Sandler boosted their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Oppenheimer began coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price target for the company. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $80.00 target price (up previously from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $68.00.

Inari Medical Trading Up 0.1 %

Shares of NARI opened at $79.97 on Friday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.99. The firm has a fifty day simple moving average of $71.49 and a 200 day simple moving average of $55.42. The stock has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Insider Buying and Selling

In other Inari Medical news, Director William Hoffman sold 60,000 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $55.66, for a total value of $3,339,600.00. Following the completion of the sale, the director now owns 441,233 shares in the company, valued at $24,559,028.78. This trade represents a 11.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the sale, the chief executive officer now owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 263,000 shares of company stock worth $15,599,470. 10.60% of the stock is owned by insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.